Scott Giacobello Sells 141,600 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CFO Scott Giacobello sold 141,600 shares of the business’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $4.13, for a total transaction of $584,808.00. Following the sale, the chief financial officer directly owned 295,224 shares in the company, valued at approximately $1,219,275.12. The trade was a 32.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Whitehawk Therapeutics Stock Performance

NASDAQ WHWK opened at $4.11 on Friday. The firm’s fifty day moving average price is $3.46 and its two-hundred day moving average price is $2.79. The stock has a market cap of $193.98 million, a PE ratio of 8.74 and a beta of 0.57. Whitehawk Therapeutics, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $4.48.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.21.

Whitehawk Therapeutics News Roundup

Here are the key news stories impacting Whitehawk Therapeutics this week:

• Positive Sentiment: Citizens/JMP initiated coverage with a “Market Outperform” and an $8.00 price target (roughly ~95% above recent levels), a catalyst that has supported buying interest ahead of impending trial data. Citizens Outperform
• Neutral Sentiment: Whitehawk’s CEO will appear in a Jones Trading Post–AACR virtual fireside chat on April 23 — a visibility event that can help inform investors but is unlikely to move the stock by itself. Fireside Chat
• Neutral Sentiment: Institutional ownership is meaningful (~52%) and coverage is mixed: a consensus “Hold” with an average target near $6.50 (some firms bullish, others negative), so analyst views are a mixed influence on price. Institutional Holdings
• Negative Sentiment: Significant insider selling this week — CFO Scott Giacobello sold 141,600 shares (4/16) and 77,000 shares (4/15) and director/officer Bryan Ball sold multiple blocks — has increased supply and likely pressured the stock. Company disclosures say the sales were to cover tax withholding on vested awards, but the size and frequency of sales reduced insiders’ stakes materially. SEC filings: CFO Form 4 and Other Insider Forms

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Friday, March 27th. JonesTrading assumed coverage on shares of Whitehawk Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 price objective on the stock. Citizens Jmp assumed coverage on shares of Whitehawk Therapeutics in a research note on Thursday. They issued a “market outperform” rating and a $8.00 price objective on the stock. Citigroup assumed coverage on shares of Whitehawk Therapeutics in a research note on Thursday. They issued an “outperform” rating on the stock. Finally, Oppenheimer assumed coverage on shares of Whitehawk Therapeutics in a research note on Thursday, February 5th. They issued an “outperform” rating and a $6.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Whitehawk Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Institutional Trading of Whitehawk Therapeutics

Institutional investors have recently bought and sold shares of the company. Quadrature Capital Ltd bought a new stake in Whitehawk Therapeutics during the fourth quarter valued at $28,000. ABG Innovation Capital Partners III GP Ltd bought a new stake in Whitehawk Therapeutics during the third quarter valued at $51,000. Dimensional Fund Advisors LP bought a new stake in Whitehawk Therapeutics during the third quarter valued at $84,000. Marshall Wace LLP bought a new stake in Whitehawk Therapeutics during the fourth quarter valued at $164,000. Finally, Jane Street Group LLC boosted its position in Whitehawk Therapeutics by 177.3% during the fourth quarter. Jane Street Group LLC now owns 69,931 shares of the company’s stock valued at $169,000 after acquiring an additional 44,716 shares during the last quarter. Institutional investors own 52.08% of the company’s stock.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.